Anebulo Pharmaceuticals, Inc. NASDAQ:ANEB

Founder-led company

Anebulo Pharmaceuticals stock price today

$2.61
+0.90
+53.53%
Financial Health
0
1
2
3
4
5
6
7
8
9

Anebulo Pharmaceuticals stock price monthly change

-31.17%
month

Anebulo Pharmaceuticals stock price quarterly change

-31.17%
quarter

Anebulo Pharmaceuticals stock price yearly change

-30.61%
year

Anebulo Pharmaceuticals key metrics

Market Cap
25.93M
Enterprise value
N/A
P/E
-6.27
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
4.55
PEG ratio
-0.06
EPS
-0.37
Revenue
N/A
EBITDA
-9.34M
Income
-9.19M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Anebulo Pharmaceuticals stock price history

Anebulo Pharmaceuticals stock forecast

Anebulo Pharmaceuticals financial statements

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Profit margin
Jun 2022 0 -2.31M
Mar 2023 0 -2.73M
Jun 2023 0 -2.49M
Mar 2024 0 -1.65M
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Analyst Estimates
2028 78.75M 15.79M 20.06%
  • Analysts Price target

  • Financials & Ratios estimates

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Debt to assets
Dec 2022 16888256 1.37M 8.13%
Mar 2023 14432606 1.49M 10.33%
Jun 2023 11670151 1.06M 9.16%
Mar 2024 5995635 1.01M 16.85%
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Cash Flow
Jun 2022 -1.99M 0 0
Mar 2023 -2.19M 0 0
Jun 2023 -2.84M 0 -68.15K
Mar 2024 -1.49M 0 0

Anebulo Pharmaceuticals alternative data

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Employee count
Aug 2023 4
Sep 2023 4
Oct 2023 2
Nov 2023 2
Dec 2023 2
Jan 2024 2
Feb 2024 2
Mar 2024 2
Apr 2024 2
May 2024 2
Jun 2024 2
Jul 2024 2

Anebulo Pharmaceuticals other data

2.94% -27.25%
of ANEB is owned by hedge funds
686.02K -6.36M
shares is hold by hedge funds

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Insider trades (number of shares)
Period Buy Sel
Dec 2021 19148 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ENGLISH ARON R. other: See Explanation of Respo..
Common Stock, par value $0.001 per share 400 $6.59 $2,634
Purchase
ENGLISH ARON R. other: See Explanation of Respo..
Common Stock, par value $0.001 per share 412 $5.9 $2,429
Purchase
ENGLISH ARON R. other: See Explanation of Respo..
Common Stock, par value $0.001 per share 4,500 $5.93 $26,685
Purchase
ENGLISH ARON R. other: See Explanation Response
Common Stock, par value $0.001 per share 13,836 $5.3 $73,331
Insider Compensation
Mr. Rex Merchant CFA (1960) Chief Financial Officer
$239,580
Dr. Daniel Schneeberger M.B.A., M.D. (1984) Chief Executive Officer & Director
$13,980
Dr. Joseph F. Lawler M.D., Ph.D. (1972) Founder & Chairman
$5,500
Wednesday, 25 September 2024
businesswire.com
Wednesday, 15 May 2024
businesswire.com
businesswire.com
Tuesday, 13 February 2024
businesswire.com
Tuesday, 14 November 2023
businesswire.com
Thursday, 19 October 2023
Zacks Investment Research
Tuesday, 22 August 2023
Zacks Investment Research
Monday, 12 June 2023
Zacks Investment Research
Wednesday, 24 May 2023
Zacks Investment Research
Friday, 27 January 2023
Seeking Alpha
Tuesday, 5 July 2022
Benzinga
Thursday, 23 June 2022
Business Wire
Friday, 11 February 2022
Benzinga
Monday, 18 October 2021
Schaeffers Research
Tuesday, 12 October 2021
Benzinga
  • What's the price of Anebulo Pharmaceuticals stock today?

    One share of Anebulo Pharmaceuticals stock can currently be purchased for approximately $2.61.

  • When is Anebulo Pharmaceuticals's next earnings date?

    Unfortunately, Anebulo Pharmaceuticals's (ANEB) next earnings date is currently unknown.

  • Does Anebulo Pharmaceuticals pay dividends?

    No, Anebulo Pharmaceuticals does not pay dividends.

  • How much money does Anebulo Pharmaceuticals make?

    Anebulo Pharmaceuticals has a market capitalization of 25.93M.

  • What is Anebulo Pharmaceuticals's stock symbol?

    Anebulo Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ANEB".

  • What is Anebulo Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Anebulo Pharmaceuticals?

    Shares of Anebulo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Anebulo Pharmaceuticals's key executives?

    Anebulo Pharmaceuticals's management team includes the following people:

    • Mr. Rex Merchant CFA Chief Financial Officer(age: 65, pay: $239,580)
    • Dr. Daniel Schneeberger M.B.A., M.D. Chief Executive Officer & Director(age: 41, pay: $13,980)
    • Dr. Joseph F. Lawler M.D., Ph.D. Founder & Chairman(age: 53, pay: $5,500)
  • Is Anebulo Pharmaceuticals founder-led company?

    Yes, Anebulo Pharmaceuticals is a company led by its founder Dr. Joseph F. Lawler M.D., Ph.D..

  • How many employees does Anebulo Pharmaceuticals have?

    As Jul 2024, Anebulo Pharmaceuticals employs 2 workers.

  • When Anebulo Pharmaceuticals went public?

    Anebulo Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 7 May 2021.

  • What is Anebulo Pharmaceuticals's official website?

    The official website for Anebulo Pharmaceuticals is anebulo.com.

  • Where are Anebulo Pharmaceuticals's headquarters?

    Anebulo Pharmaceuticals is headquartered at 1415 Ranch Road 620 South, Lakeway, TX.

  • How can i contact Anebulo Pharmaceuticals?

    Anebulo Pharmaceuticals's mailing address is 1415 Ranch Road 620 South, Lakeway, TX and company can be reached via phone at +51 25980931.

Anebulo Pharmaceuticals company profile:

Anebulo Pharmaceuticals, Inc.

anebulo.com
Exchange:

NASDAQ

Full time employees:

2

Industry:

Biotechnology

Sector:

Healthcare

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

1415 Ranch Road 620 South
Lakeway, TX 78734

CIK: 0001815974
ISIN: US0345691036
CUSIP: 034569103